Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Operating Cash Flow
Cash generated by the company's core business operations during the period.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $4.7M (cash outflow) rose 156.3% year over year, ahead of the +74.6% change in trailing-twelve-month operating cash flow. Sequentially, it rose 48.1% from the prior quarter. Over 3 fiscal years it compounded at +16.9% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +156.3% holds above the trailing-twelve-month pace of +74.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (9.91M) USD
- Year-over-year change
- -36.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.91M) | -36.4% |
| FY2024 | 2024-12-31 | (7.27M) | -12.2% |
| FY2023 | 2023-12-31 | (6.48M) | -4.5% |
| FY2022 | 2022-12-31 | (6.2M) | -44.5% |
| FY2021 | 2021-12-31 | (4.29M) | — |
Operating Cash Flow vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +74.6% is the 3rd highest of 8, against a peer median of +18.8%.
- Over three fiscal years its annual growth of +16.9% compares with a peer median of +5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $87.53M USD | -39.9% | -3.4% | 70.7% | |
| LTM Mar 2026 | $48.47M USD | +3.0% | -9.9% | 322.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $38.99M USD | +35.1% | — | 325.3% |
| LTM Mar 2026 | $33.46M USD | +84.2% | -11.8% | 446.5% | |
| LTM Mar 2026 | $32.07M USD | +157.5% | +47.8% | — | |
| LTM Mar 2026 | CA$30.89M CAD | +18.8% | +5.7% | — | |
| LTM Mar 2026 | $27.3M USD | — | +54.4% | — | |
| LTM Mar 2026 | $20.25M USD | -34.9% | +9.9% | — | |
| LTM Mar 2026 | $12.78M USD | +74.6% | +16.9% | — | |
| Peer median (excluding GLSI) | — | +18.8% | +5.7% | 323.8% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.57M) | (7.83M) | (8.89M) | (15.79M) | (19.36M) |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Deferred Income Tax | (1.19M) | (1.75M) | 0 | 0 | 0 |
| Stock-Based Compensation | 660.58K | 1.74M | 2.38M | 7.25M | 6.8M |
| Change in Working Capital | (385.17K) | (122.27K) | 31.5K | 1.27M | 2.64M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (526.73K) | 0 | 35.47K | 921.22K | 2.07M |
| Other Working Capital | 141.57K | (122.27K) | (3.97K) | 344.11K | 568.12K |
| Other Non-Cash Items | 1.19M | 1.75M | 0 | 0 | 0 |
| Operating Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
| Capital Expenditures | 0 | (3) | 0 | 3 | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 3.11M | 0 | 0 | 4.37M | 12M |
| Common Stock Repurchased | 0 | (7.54M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (275.15K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 2.84M | (7.54M) | 0 | 4.37M | 12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.46M) | (13.74M) | (6.48M) | (2.9M) | 2.09M |
| Free Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.